- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
MGC Pharma Receives First Government Grant for Clinical Trial
MGC Pharma announced it’s received government funding for its clinical trial with the University of Notre Dame Western Australia.
MGC Pharmaceuticals (ASX:MXC) announced on Tuesday (November 12) it’s received funding from the Australian Commonwealth Government for its clinical trial in collaboration with the University of Notre Dame Western Australia.
As quoted in the press release:
Key Highlights:
First AU$25,000 of the AU$50,000 Grant received
The Grant supports the CogniCann® Phase IIb clinical trial being conducted in collaboration with the University of Notre Dame Western Australia
Securing the Grant demonstrates the Australian Governments’ support for the Company’s stated growing Research & Development agenda, alongside broader continued research into the therapeutic use of phytocannabinoids
The Phase IIb double-blind placebo controlled clinical trial is assessing symptoms associated with dementia and Alzheimer’s disease
Click here to read the full press release.
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.